ICYMI: Highlights From RAD 2023

Our top coverage featuring this year’s Revolutionizing Atopic Dermatitis (RAD) 2023 conference surrounded the unique and oftentimes challenging treatment landscape for patients with AD, as well as the disparities within dermatologic patient care that still need to be addressed.

These are your top RAD 2023 conference highlights. Click here for all our coverage from this conference.

Dr Larry Eichenfield: A Changing Therapy Landscape Provides More Options for Infants With AD

In this interview, Larry Eichenfield, MD, professor of dermatology and pediatrics and vice chair of the Department of Dermatology at the University of California San Diego School of Medicine, and chief of pediatric and adolescent dermatology at Rady Children's Hospital San Diego, shared key points he hoped physicians took away from his session on choosing the right treatments and therapies for AD in infants.

Posters Show Ruxolitinib Cream to Be Both Effective and Safe for Treating AD

Two posters provided insights into the safety and efficacy of ruxolitinib cream for AD and chronic hand dermatitis (CHD). The first poster analyzed safety reports during the first year of market approval, finding no systemic adverse events and a low incidence of application site reactions, indicating that ruxolitinib cream was well tolerated. The second poster presented interim results of a study testing the efficacy of ruxolitinib 1.5% cream in CHD, showing promising results with reductions in Investigator Global Assessment scores, hand eczema severity index, and itch levels after 4 weeks of treatment.

Symposium Highlights New Research on JAK, PDE-4 Inhibitors

In this symposium, Dr Eichenfield discussed innovations in nonsteroid topical therapies for AD, highlighting the efficacy and safety of topical ruxolitinib 1.5% cream in patients 12 years and older. Meanwhile, Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology and director of clinical research and contact dermatitis at The George Washington University School of Medicine and Health Sciences in Washington, DC, presented insights into oral Janus kinase (JAK) inhibitors for AD.

Panel Focuses on Burgeoning Therapies in Atopic Dermatitis

This symposium featured a panel discussing upcoming treatments for AD, including nonsteroidal topicals and biologics. Melinda Gooderham, MD, MSc, FRCPC, reviewed medications like tapinarof and roflumilast expected by 2024, presenting positive results from phase 3 trials, while David Rosmarin, MD, highlighted early-stage developments, emphasizing promising outcomes in treatments targeting microbial, itch, and adaptive immune system pathways for AD.

Disparities in AD Treatment: What Can Be Done?

The final symposium at RAD 2023 addressed disparities in care for patients of color with AD. Panelists, including Andrew Alexis, MD, MPH, FAAD, vice chair for diversity and inclusion for the Department of Dermatology and a dermatologist at the Center for Diverse Skin Complexions at Weill Cornell Medicine in New York City, highlighted the higher prevalence of diagnosed AD among patients of color and the impact on their quality of life.